Catalyst Biosciences

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

Catalyst Biosciences, Inc. (CBIO) delivered earnings and revenue surprises of 5.88% and 13.20%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Biosciences, Inc. (CBIO) Reports Q2 Loss, Tops Revenue Estimates

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the second quarter ended June 30, 2021, and provided a corporate update.

Catalyst Biosciences Reports Second Quarter 2021 Operating & Financial Results and Provides a Corporate Update

Catalyst Biosciences, Inc. (CBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalyst Biosciences, Inc. (CBIO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Launching the ConFIrm study to identify patients with Complement Factor I deficiencies Launching the ConFIrm study to identify patients with Complement Factor I deficiencies

Catalyst Biosciences Announces First Patient Screened for CFI deficiency in its CB 4332 Screening and Natural History of Disease Studies

SOUTH SAN FRANCISCO, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented four posters at the International Society for Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress, being held July 17-21, 2021.

Catalyst Biosciences Presents Four Posters at the International Society for Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress

Grant Blouse, Ph.D., M.Sc. appointed chief scientific officer

Catalyst Biosciences Announces Key Leadership Changes in its Ongoing Transition to an Integrated Protease Medicines Company

SOUTH SAN FRANCISCO, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced four poster presentations on marzaptacog alfa (activated) (MarzAA) and dalcinanonog alfa (DalcA) at the upcoming International Society on Thrombosis and Haemostatis (ISTH) Virtual Congress being held from July 17-21, 2021.

Catalyst Biosciences Announces Presentations at the International Society on Thrombosis and Haemostasis

SOUTH SAN FRANCISCO, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development day on its protease medicines platform focusing on the regulation of complement including CB 4332 on Monday, July 19, 2021 at 12:00 pm Eastern Time.

Catalyst Biosciences to Host Research and Development Day on CB 4332 and Complement Programs

Second Fast Track Designation for MarzAA Second Fast Track Designation for MarzAA

Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Factor VII Deficiency

Sphere 3D

Iterum Therapeutics Plc

GEE Group

SeaChange International

Electrameccanica

Vislink Technologies Inc

VistaGen Therapeutics

Which penny stocks are investors watching as June comes to an end? The post 8 Penny Stocks to Watch Right Now As June Comes to an End appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

8 Penny Stocks to Watch Right Now As June Comes to an End

Catalyst Biosciences (CBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Catalyst Biosciences (CBIO) This Earnings Season?

Catalyst Biosciences, Inc. (CBIO) delivered earnings and revenue surprises of -2.60% and 46.70%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Biosciences, Inc. (CBIO) Reports Q1 Loss, Tops Revenue Estimates

SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Catalyst Biosciences Reports First Quarter 2021 Operating & Financial Results and Provides a Corporate Update

CB 2782-PEG patent protection extended until at least 2038 CB 2782-PEG patent protection extended until at least 2038

Catalyst Biosciences Expands its Protease Medicines Patent Portfolio of Complement Factor 3 Degraders

SOUTH SAN FRANCISCO, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference at 3:00 pm ET on Thursday, April 15, 2021.

Catalyst Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and full-year ending December 31, 2020 and provided a corporate update.

Catalyst Biosciences Reports Fourth Quarter and Full-Year 2020 Operating & Financial Results and Provides a Corporate Update

Plains All American Pipeline

Kadmon Hlds

Resonant

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Stocks to Buy Now Trading Under $10 With Plenty of Upside Potential

SOUTH SAN FRANCISCO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the “Company”) today announced that in connection with its previously announced public offering of its common stock, the underwriters partially exercised and closed their over-allotment option to purchase an additional 485,000 shares of the Company's common stock, offered at a price of $5.75 per share to the public. The Company received approximately $2.8 million in additional gross proceeds from the sale of these shares, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. All of the shares in the offering were sold by the Company.

Catalyst Biosciences Announces Partial Exercise and Closing of Over-Allotment Option in Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented positive pre-clinical data from its Marzeptacog alfa (activated) – MarzAA, program, the Company's subcutaneously (SQ) administered next-generation engineered activated coagulation Factor VII (FVIIa) for the treatment of episodic bleeding that is entering a Phase 3 registration trial. The data were presented by Tom Knudsen, D.V.M., Ph.D., vice president of translational research and Howard Levy, M.B.B.Ch., Ph.D., M.M.M., chief medical officer in poster sessions at the virtual 14th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD).

Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD Congress

SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the “Company”) today announced the closing of an underwritten public offering of 8,700,000 shares of its common stock, offered at a price of $5.75 per share to the public. The gross proceeds to the Company from this offering were approximately $50 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. All of the shares in the offering were sold by the Company.

Catalyst Biosciences Announces Closing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO (the “Company”) today announced the pricing of an underwritten public offering of 8,700,000 shares of its common stock, offered at a price of $5.75 per share to the public. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,305,000 shares of its common stock. All of the shares in the offering are being offered by the Company. The offering is expected to close on or about January 29, 2021, subject to customary closing conditions.

Catalyst Biosciences Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that it is offering shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Catalyst expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering at the public offering price less the underwriting discounts and commissions. All of the shares in the offering are being offered by Catalyst.

Catalyst Biosciences Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced two e-poster presentations at the European Association for Haemophilia and Allied Disorders (EAHAD) Virtual Congress being held on February 3 - 5, 2021.

Catalyst Biosciences Announces Poster Presentations at the EAHAD 2021 Virtual Congress

SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its management team will participate in a fireside chat hosted by LifeSci Capital on Tuesday, January 19, 2021 at 1:00 pm Eastern Time.

Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) presented a poster today at the 62nd Annual American Society of Hematology (ASH) meeting, held virtually December 5-8, 2020, highlighting its Phase 3 Study, Crimson 1. The study will evaluate Marzeptacog alfa (activated) – or MarzAA, the Company's subcutaneously administered next-generation engineered coagulation Factor VIIa (FVIIa).

News for Catalyst Biosciences Stock (CBIO)